Evaluation of early response to antiangiogenic treatment with dynamic contrast enhanced ultrasound;Évaluation précoce des traitements anti-angiogéniques par échographie dynamique de contraste

Journal de Radiologie

Volumn 89, Issue 5 C1, 2008, Pages 549-555

  Lassau, N ^a   Brule, A ^a   Chami, L ^a   Benatsou, B ^a   Peronneau P ^a   Roche, A ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Angiogenesis; Contrast material; Doppler; Treatment; Ultrasound

Indexed keywords

ANGIOGENESIS INHIBITOR; IMATINIB; SHU 508; SONOVUE; SORAFENIB; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DRUG EFFICACY; ECHOGRAPHY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMAGE ANALYSIS; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; REPRODUCIBILITY; REVIEW; TUMOR VASCULARIZATION; DOPPLER FLOWMETRY; IMAGE ENHANCEMENT; METHODOLOGY; NEOPLASM; SENSITIVITY AND SPECIFICITY; TIME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CONTRAST MEDIA; HUMANS; IMAGE ENHANCEMENT; NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; ULTRASONOGRAPHY, DOPPLER;

EID: 44949227010     PISSN: 02210363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0221-0363(08)71480-X     Document Type: Article

References (44)

1. Rehman S, Jayson G. Molecular Imaging of Antiangiogenic agents. Oncologist 2005;10:92-103.
2. World Health Organisation Offset Publication, editor. WHO Handbook for Reporting Results of Cancer Treatment. Geneva (Switzerland), 1979.
3. Zerhouni EA. Major trends in the imaging sciences. 93st Scientific Assembly and Annual Meeting of Radiological Society of North America 2007:57.
4. Benjamin RS, Choi H, Macapinlac HA et al. Response of gastrointestinal stromal tumors (GISTs) to imatinib by Choi criteria and response evaluation criteria in solid tumors (RECIST) as surrogates for survival and time to progression. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006:9506.
5. Therasse P, Arbuck SG, Eisenhaur EA et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
6. th Scientific Assembly and Annual Meeting, Chicago. Proc Radiology 115. 2004.
7. Cosgrove D. Angiogenesis imaging - Ultrasound. Br J Radiol 2003;76:43-9.
8. Lassau N, Chawi I, Rouffiac V, Bidault S, Escudier B, Leclere J. Interest of colour Doppler ultrasonography to evaluate a new anti-angigenic treatment with thalidomide in metastatic renal call carcinoma. Bull Cancer 2004;91:629-35.
9. Lassau N, Paturel-Asselin C, Guinebretière JM et al. New haemodynamic approach to angiogenesis: colour and pulsed Doppler ultrasonography. Invest Radiol 1999;34:194-8.
10. Asselin C, Lassau N, Guinebretière JM et al. The in vivo murineiterleukin-12 transfer by the Semliki Forest Virus induces B16 tumour regression through inhibition of tumour blood vessel formation monitored by Doppler unltrasonography. Gene Therapy 199;4:606-15.
11. Kaliski A, Maggiorella L, Mathé D, Rouffiac V, Opolon P, et al. Angiogenic and Tumor Growth Inhibition by an MMP-inhibitor Targeting Radio -Induced MMP-2 and VEGF. Mol Cancer Ther 2005;4:1717-28.
12. Escudier B, Lassau N, Couanet D et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 2002;13:1029-35.
13. Faivre S, Delbaldo C, Vera K, Lozahic S, Lassau N, Bello C, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
14. Hochedez P, Lassau N, Bonvalot S, Bidault S, Leclere J, Avril MF. Traitement des récidives locales et en transit des mélanomes par perfusion de membre isolé: Intérêt de l'Échographie- Doppler. J Radiol 2003;84:597-603.
15. Lassau N, Koscielny S, Opolon P et al. Évaluation of contrast-enhanced colour Doppler ultrasound for the quantification of angiogenenis in vivo. Invest Radiol 2001;36:50-5.
16. Lassau N, Lamuraglia M, Vanel D et al. Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol 2005;16:1054-60.
17. Eggermont AM. Evolving imaging technology: contrast-enhanced Doppler ultrasound is early and rapid predictor of tumour response. Ann Oncol 2005;16:995-6.
18. Lassau N, Lamuraglia M, Leclere J, Rouffiac V. Évaluation fonctionnelle et précoce des traitements en cancérologie: intérêt des produits de contraste ultrasonores. J Radiol 2004;85:704-12.
19. Lassau N, Leclère J, Peronneau P. Follow-up of Oncology Patients Undergoing Chemotherapy. Enhancing the Role of Ultrasound with Contrast Agents. Springer, Ed R. Lencioni 2006:77-88.
20. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999;23:82-7.
21. van Oosterom AT, Judson IR, Verweij J et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38:S83-7.
22. De Giorgi U, Aliberti C, Benea G et al. Effect of angiosonography to monitor response during Imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 2005;11:6171-6.
23. Chen MY, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GIST) treated with Gleevec (imatinib mesylate). AJR Am J Roentgenol 2002;179:1059-62.
24. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos Ap et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005;16:566-78.
25. Blay JY, Landi B, Bonvalot S, Monges G, Ray-Coquard I, Duffaud F et al. Recommendations for the management of GIST patients. Bull Cancer 2005;92:907-18.
26. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25;1753-9.
27. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C. We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760-4.
28. Lassau N, Lamuraglia M, Chami L, Leclère J, Bonvalot S, Terrier et al. Gastrointestinal stromal tumours treated with Imatinib: Monitoring response with contrast enhanced ultrasound. AJR Am J Roentgenol. 2006;187:1267-73.
29. Lamuraglia M, Le Cesne A, Chami L, Bonvalot S, et al. Dynamic contrast-enhanced Doppler ultrasound (DCE-US) is a useful radiological assessment to early predict the outcome of patients with gastrointestinal stromal tumors (GIST) treated with imatinib (IM). J Clin Oncology. 2006 ASCO Annual Meeting Proceedings. June 20, Vol 24:529S.
30. Lamuraglia M, Escudier B, Chami L, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 2006;42:2472-9.
31. Escudier B, Lassau N, Angevin E, Soria JC, Chami L, et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007;13:1801-9.
32. Claassen L, Seidel G, Algermissen C. Quantification of flow rates using harmonic grey-scale imaging and an ultrasound contrast agent: an in vitro and in vivo study. Ultrasound Med Biol 2001;27:83-8.
33. Yeh C, Yang M, Li P. Contrast-specific ultrasonic flow measurements based on both input and outpout time intensities. Ultrasound Med Biol 2003;29:671-8.
34. Brule A, Lassau N, Koscienly S, Lavisse S, Roche A, Peronneau P. Relevance of ultrasonic linear raw data compared to video data for tumor perfusion quantification. 93st Scientific Assembly and Annual Meeting of Radiological Society of North America. 2007:545.
35. Lucidarme O, Taillade L, Guibal A, Mule S, Comperat E, Badachi Y. Noninvasive quantitative assessment of tumor microcirculation using contrast-enhanced functional ultrasound imaging (FUSI) in murine model: study of the rebound effect after suspension of anti-VEGF therapy. 93st Scientific Assembly and Annual Meeting of Radiological Society of North America. 2007:545.
36. Niermann KJ, Fleischer AC, Huamani J et al. Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography J Ultrasound Med 2007;26:749-56.
37. Lavisse S, Lejeune P, Rouffiac V et al. Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using Dynamic Contrast-Enhanced Ultrasonography (DCE-US). Investigative Radiology. In press (February 2008).
38. Armand JP, Loriot Y, Ropert S, Catteau A, Soria JC, Lassau N. Perfusion assessment of tumors by doppler ultrasonography, a tool for early evaluation of targeted antiangiogenic compounds. Annals of Oncology 2006;17:iii21.
39. Buonaccorsi GA, Roberts C, Cheung S, et al. Tracer kinetic medol-driven registration for dynamic contrast enhanced MRI time series. Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist Interv 2005;8:91-8.
40. Lassau N, Bouaita L, Chami L, Benatsou B, Pellier J, Escudier B. Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification for the early evaluation of metastatic renal cancer treated with tyrosine kinas inhibitors. 93st Scientific Assembly and Annual Meeting of Radiological Society of North America. 2007:545.
41. Lassau N, Chami L, Peronneau P, Koscielny S, Benatsou B, Roche A. Comparative DEC-US study of different tumoral perfusion parameters in patients with GIST treated by targeted treatment. 93st Scientific Assembly and Annual Meeting of Radiological Society of North America. 2007:365.
42. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005:307:58-62.
43. Tranquart F. Développements récents en imagerie ultrasonore de contraste à visée oncologique. J Radiol 2007;88:1759-69.
44. Lassau N, Chami L, Koscielny S, Pellier J, Peronneau P, Soria J. Study of different tumor perfusion parameters provided by DCE-US in patients treated with targeted treatments in phase I. 93st Scientific Assembly and Annual Meeting of Radiological Society of North America. 2007:364.